A rat model establishment of bronchopulmonary dysplasia-related lung & brain injury within 28 days after birth DOI Creative Commons
Xin Lin, Meicen Zhou, Hua Wang

et al.

BMC Neuroscience, Journal Year: 2024, Volume and Issue: 25(1)

Published: Nov. 28, 2024

Lung injury associated with bronchopulmonary dysplasia (BPD) and its related neurodevelopmental disorders have garnered increasing attention in the context of premature infants. Establishing a reliable animal model is essential for delving into underlying mechanisms these conditions. Newborn rats were randomly assigned to two groups: hyperoxia-induced BPD group normoxia (NO) group. For group, they nurtured hyperoxic environment high oxygen inspired fraction (0.85) from birth until day 14 within 28 days postnatally. In contrast, NO consisted newborn that normoxic standard (0.21) Various pathological sections both lung brain tissues examined. TUNEL staining, immunofluorescence assays, functional tests performed, results meticulously analyzed assess impact hyperoxia environments on developing organs. significant reduction alveolar number coupled enlargement was observed, alongside severe fibrosis, collagen deposition, constriction bronchi vascular lumens. This accompanied by an accumulation inflammatory cells marked deterioration function compared (P < 0.05). Additionally, decrease neuronal count, increase apoptosis, proliferation neuroglia cells, demyelination noted, poorer performance Morris water maze test The BPD-rats established successfully. evident across alveoli pulmonary vessels, which deteriorated at postnatal 14. Concurrently, extended cerebral cortex hippocampus, impaired orientation navigation spatial probe 28.

Language: Английский

Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system DOI Creative Commons

Raúl A Dulce,

Konstantinos Chatzistergos, Rosemeire M. Kanashiro‐Takeuchi

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Abstract Growth hormone (GH)-releasing (GHRH), a hypothalamic peptide initially characterized for its role in GH regulation, has gained increasing attention due to GH-independent action on peripheral physiology, including that of the cardiovascular system. While effects vasculature are still under investigation, GHRH and synthetic agonists have exhibited remarkable receptor-mediated cardioprotective properties preclinical models. analogs enhance myocardial function by improving contractility, reducing oxidative stress, inflammation, offsetting pathological remodeling. Studies performed small large animal models demonstrated efficacy these compounds diverse cardiomyopathies, suggesting their potential as promising therapeutic agents. However, clinical translation faces challenges related route administration side mainly associated with activation GH/IGF-I axis. Despite hurdles, compelling evidence supporting cardiac repair makes attractive candidates testing treatment various diseases.

Language: Английский

Citations

2
Growth hormone-releasing hormone receptor (GHRH-R) and its signaling DOI Creative Commons

Gábor Halmos,

Zsuzsanna Szabó, Nikoletta Dobos

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Abstract The hypothalamic polypeptide growth hormone-releasing hormone (GHRH) stimulates the secretion of (GH) from pituitary through binding and activation type GHRH receptor (GHRH-R), which belongs to family G protein-coupled receptors with seven potential membrane-spanning domains. Various splice variants GHRH-R (SV) in human neoplasms other extrapituitary tissues were demonstrated their cDNA was sequenced. Among SVs, variant 1 (SV1) possesses greatest similarity full-length remains functional by eliciting cAMP signaling mitogenic activity upon stimulation GHRH. In this review, we briefly discuss activation, regulation, molecular mechanisms pathways GHRH-Rs SVs various also summarize expression, biological activities function GHRH, its analogs receptors. A large body work have extensively studied evaluated clinical applications agonists antagonists diverse fields, including oncology, endocrinology, obesity, diabetes, metabolic dysfunctions, cardiology, immune functions, mood disorders, Alzheimer’s lung disease, ophthalmology, inflammation, wound healing applications. These results strongly support therapeutic use medicine near future.

Language: Английский

Citations

2
Growth hormone – releasing hormone in the immune system DOI Creative Commons
Agnieszka Siejka, Hanna Ławnicka,

Saikat Fakir

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

Abstract GHRH is a neuropeptide associated with diverse variety of activities in human physiology and immune responses. The present study reviews the latest information on involvement system inflammation, suggesting that antagonists may deliver new therapeutic possibility disorders related to dysfunction inflammation.

Language: Английский

Citations

8
Growth hormone-releasing hormone and cancer DOI
Iacopo Gesmundo, Francesca Pedrolli,

Renzhi Cai

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Language: Английский

Citations

7
Growth hormone-releasing hormone and its analogues in health and disease DOI
Riccarda Granata, Sheila Leone, Xianyang Zhang

et al.

Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 13, 2024

Language: Английский

Citations

7
Effects of GHRH and its analogues on the Vascular System DOI
Hong Yu, Huan Peng

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Language: Английский

Citations

3
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders DOI Creative Commons
Andrew V. Schally,

Renzhi Cai,

Xianyang Zhang

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 26, 2024

Abstract Growth Hormone-Releasing Hormone (GHRH) and its analogs have gained significant attention for their therapeutic potential across various domains, including oncology, regenerative medicine, metabolic disorders. Originally recognized role in regulating growth hormone (GH) secretion, GHRH has since been discovered to exert broader physiological effects beyond the pituitary gland, with receptors identified multiple extrahypothalamic tissues, tumor cells. This review explores development of both agonists antagonists, focusing on mechanisms action, applications, future potential. shown promise promoting tissue regeneration, improving cardiac function, enhancing islet survival diabetes. Meanwhile, particularly those MIA AVR series, demonstrate potent antitumor activity by inhibiting cancer cell proliferation downregulating factor pathways, while also exhibiting anti-inflammatory properties. Preclinical studies models lung, prostate, breast, gastrointestinal cancers indicate that could offer a novel approach minimal toxicity. Additionally, antagonists are being investigated treating neurodegenerative diseases inflammatory conditions. highlights versatility as promising class agents, poised impact fields medicine.

Language: Английский

Citations

3
A rat model establishment of bronchopulmonary dysplasia-related lung & brain injury within 28 days after birth DOI Creative Commons
Xin Lin, Meicen Zhou, Hua Wang

et al.

BMC Neuroscience, Journal Year: 2024, Volume and Issue: 25(1)

Published: Nov. 28, 2024

Lung injury associated with bronchopulmonary dysplasia (BPD) and its related neurodevelopmental disorders have garnered increasing attention in the context of premature infants. Establishing a reliable animal model is essential for delving into underlying mechanisms these conditions. Newborn rats were randomly assigned to two groups: hyperoxia-induced BPD group normoxia (NO) group. For group, they nurtured hyperoxic environment high oxygen inspired fraction (0.85) from birth until day 14 within 28 days postnatally. In contrast, NO consisted newborn that normoxic standard (0.21) Various pathological sections both lung brain tissues examined. TUNEL staining, immunofluorescence assays, functional tests performed, results meticulously analyzed assess impact hyperoxia environments on developing organs. significant reduction alveolar number coupled enlargement was observed, alongside severe fibrosis, collagen deposition, constriction bronchi vascular lumens. This accompanied by an accumulation inflammatory cells marked deterioration function compared (P < 0.05). Additionally, decrease neuronal count, increase apoptosis, proliferation neuroglia cells, demyelination noted, poorer performance Morris water maze test The BPD-rats established successfully. evident across alveoli pulmonary vessels, which deteriorated at postnatal 14. Concurrently, extended cerebral cortex hippocampus, impaired orientation navigation spatial probe 28.

Language: Английский

Citations

0